These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 26851597

  • 1. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.
    Athauda D, Foltynie T.
    Drug Discov Today; 2016 May; 21(5):802-18. PubMed ID: 26851597
    [Abstract] [Full Text] [Related]

  • 2. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
    Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH.
    Cell Transplant; 2017 Sep; 26(9):1560-1571. PubMed ID: 29113464
    [Abstract] [Full Text] [Related]

  • 3. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
    Hölscher C.
    Expert Opin Investig Drugs; 2020 Apr; 29(4):333-348. PubMed ID: 32175781
    [Abstract] [Full Text] [Related]

  • 4. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J, Blunt E, Gupta D, Edison P.
    Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
    [Abstract] [Full Text] [Related]

  • 5. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.
    Athauda D, Foltynie T.
    Neuropharmacology; 2018 Jul 01; 136(Pt B):260-270. PubMed ID: 28927992
    [Abstract] [Full Text] [Related]

  • 6. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
    Hölscher C.
    Neuropharmacology; 2018 Jul 01; 136(Pt B):251-259. PubMed ID: 29402504
    [Abstract] [Full Text] [Related]

  • 7. GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight.
    Monti G, Gomes Moreira D, Richner M, Mutsaers HAM, Ferreira N, Jan A.
    Cells; 2022 Jun 25; 11(13):. PubMed ID: 35805109
    [Abstract] [Full Text] [Related]

  • 8. Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease.
    Verma A, Goyal A.
    Eur J Pharmacol; 2024 Nov 05; 982():176936. PubMed ID: 39182542
    [Abstract] [Full Text] [Related]

  • 9. Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
    Batista AF, Bodart-Santos V, De Felice FG, Ferreira ST.
    CNS Drugs; 2019 Mar 05; 33(3):209-223. PubMed ID: 30511349
    [Abstract] [Full Text] [Related]

  • 10. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
    Hölscher C.
    Sheng Li Xue Bao; 2014 Oct 25; 66(5):497-510. PubMed ID: 25331995
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic potential of spinal GLP-1 receptor signaling.
    Zhang D, Lv G.
    Peptides; 2018 Mar 25; 101():89-94. PubMed ID: 29329976
    [Abstract] [Full Text] [Related]

  • 12. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
    Kopp KO, Glotfelty EJ, Li Y, Greig NH.
    Pharmacol Res; 2022 Dec 25; 186():106550. PubMed ID: 36372278
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.
    Yang X, Feng P, Ji R, Ren Y, Wei W, Hölscher C.
    Expert Opin Ther Targets; 2022 May 25; 26(5):445-460. PubMed ID: 35584372
    [Abstract] [Full Text] [Related]

  • 14. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.
    Glotfelty EJ, Olson L, Karlsson TE, Li Y, Greig NH.
    Expert Opin Investig Drugs; 2020 Jun 25; 29(6):595-602. PubMed ID: 32412796
    [Abstract] [Full Text] [Related]

  • 15. Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.
    Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, Chawla S, Chowdhury K, Skene SS, Greig NH, Kapogiannis D, Foltynie T.
    JAMA Neurol; 2019 Apr 01; 76(4):420-429. PubMed ID: 30640362
    [Abstract] [Full Text] [Related]

  • 16. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.
    Hölscher C.
    Biochem Soc Trans; 2014 Apr 01; 42(2):593-9. PubMed ID: 24646283
    [Abstract] [Full Text] [Related]

  • 17. Is Exenatide a Treatment for Parkinson's Disease?
    Athauda D, Wyse R, Brundin P, Foltynie T.
    J Parkinsons Dis; 2017 Apr 01; 7(3):451-458. PubMed ID: 28777758
    [Abstract] [Full Text] [Related]

  • 18. Mitral cells and the glucagon-like peptide 1 receptor: The sweet smell of success?
    Bagnoli E, FitzGerald U.
    Eur J Neurosci; 2019 Feb 01; 49(4):422-439. PubMed ID: 30120857
    [Abstract] [Full Text] [Related]

  • 19. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.
    Calsolaro V, Edison P.
    CNS Drugs; 2015 Dec 01; 29(12):1023-39. PubMed ID: 26666230
    [Abstract] [Full Text] [Related]

  • 20. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.
    Hölscher C.
    CNS Drugs; 2012 Oct 01; 26(10):871-82. PubMed ID: 22938097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.